News in brief - June 2013

Other new launches, licence changes and prescribing updates relevant to general practice.

Orlistat is used together with dieting in obese patients with BMI ≥30kg/m2, or BMI ≥28kg/m2 with associated risk factors.
Orlistat is used together with dieting in obese patients with BMI ≥30kg/m2, or BMI ≥28kg/m2 with associated risk factors.
  • The anti-obesity agent orlistat (Xenical) is now available as generic capsules.
  • A new presentation of the hepatitis A vaccine Vaqta has been launched for adults.
  • Manufacturers of the FreeStyle InsulinX and OneTouch Verio (‘Pro’ and ‘IQ’) blood glucose meters have warned that the meters can give incorrect readings at very high glucose levels (≥56.8mmol/l) and may need to be returned for replacement.
  • Clomethiazole oral solution (formerly Heminevrin Syrup) has been relaunched; it is licensed for use as a anxiolytic and hypnotic,
  • NICE has updated its guidance on Xolair (omalizumab) in severe persistent allergic asthma, including approval from 6 years of age. 
  • Owing to manufacturing difficulties, the growth deficiency treatment Increlex (mecasermin) will be out of stock from August 2013; prescribers are advised to restrict use to existing patients. 
  • The meningitis ACW134Y vaccine Menveo, in a new presentation containing the solvent in a vial rather than a pre-filled syringe, is now licensed for use ifrom 2 years of age.
Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more